Amgen joins neuroscience exodus 31-Oct-2019 By Ben Hargreaves In third quarter financials, Amgen announces that it will end its R&D efforts in neuroscience to focus on diseases with a ‘large public health impact.
Novartis knocked back by UK on first-in-class migraine treatment 10-Jan-2019 By Ben Hargreaves Novartis' treatment for migraines is rejected by NICE on cost-effectiveness grounds, and lack of long-term data.
Novartis’ mAb becomes first for migraines in EU 01-Aug-2018 By Ben Hargreaves The European Commission has given its approval for Novartis’ Aimovig, the treatment designed specifically for patients with migraines.